This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Salud financiera de hoja de balance de Reunion Neuroscience

Salud financiera controles de criterios 4/6

Reunion Neuroscience tiene un patrimonio de los accionistas total de CA$21.3M y una deuda total de CA$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CA$29.7M y CA$8.4M respectivamente.

Información clave

Ratio deuda-patrimonio

CA$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CA$27.20m
Patrimonio	CA$21.30m
Total pasivo	CA$8.44m
Activos totales	CA$29.74m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CA$29.7M) de REUN superan a sus pasivos a corto plazo (CA$8.4M).

Pasivo a largo plazo: REUN no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: REUN está libre de deudas.

Reducción de la deuda: REUN no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: REUN tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: REUN tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 48.9% cada año

This company has been acquired

Salud financiera de hoja de balance de Reunion Neuroscience

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Reunion Neuroscience Inc. Files Form 15

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

Recent updates

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investors

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. Files Form 15

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104

High number of new directors

Reunion Neuroscience Inc. to Report Q2, 2023 Results on Nov 14, 2022

High number of new and inexperienced directors

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Announces Executive Changes

Reunion Neuroscience announces resignation of director, general counsel

Reunion Neuroscience Inc. Appoints Greg Mayes as President

Reunion Neuroscience appoints Greg Mayes as President and CEO

High number of new and inexperienced directors

Field Trip Health&nbsp; GAAP EPS of -C$0.09

Field Trip Health Ltd., Annual General Meeting, Sep 29, 2022

Field Trip Health Ltd. completed the Split-Off of Field Trip Health & Wellness Ltd.

Field Trip Health Ltd. to Report Q1, 2023 Results on Aug 15, 2022

Field Trip Health Ltd. Announces First Successful Dosings in the Phase 1 Clinical Study Entitled A Double-Blind

Field Trip Health receives final court approval for clinics business spin-out

Field Trip Health Ltd. to Report Q4, 2022 Results on Jun 29, 2022

High number of new directors

Field Trip Health Ltd. Receives U.S. Patent Covering Novel Psychedelic Molecule FT-104

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Field Trip Health Ltd. to Report Q3, 2022 Results on Feb 15, 2022

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Field Trip Launches Site Management Organization Services

Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)

Less than half of directors are independent

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

Less than half of directors are independent

First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)

Less than half of directors are independent

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. has completed a Follow-on Equity Offering in the amount of CAD 82.875 million.

Field Trip Health Ltd. to Report Q3, 2021 Results on Feb 16, 2021

Field Trip Health Ltd. Announces Participation in a Maps-Sponsored Multi-Site Study of Mdma-Assisted Therapy to Treat Eating Disorders

Field Trip Health Ltd. has completed a Composite Units Offering in the amount of CAD 17.406 million.

Field Trip Health Ltd. to Report Q2, 2021 Results on Nov 30, 2020

Field Trip Health Ltd. and Whoop Announces Partnership to Measure Effect of Psychedelic Therapies on Physiology and Mental Health

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera

Field Trip Health GAAP EPS of -C$0.09